Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Current Deferred Revenue: 2022-2025

Historic Current Deferred Revenue for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $5.8 million.

  • Stoke Therapeutics' Current Deferred Revenue fell 81.77% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year decrease of 81.77%. This contributed to the annual value of $19.0 million for FY2024, which is 24.05% up from last year.
  • Per Stoke Therapeutics' latest filing, its Current Deferred Revenue stood at $5.8 million for Q3 2025, which was down 34.13% from $8.7 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Current Deferred Revenue peaked at $31.6 million during Q3 2024, and registered a low of $5.8 million during Q3 2025.
  • Its 3-year average for Current Deferred Revenue is $16.0 million, with a median of $15.3 million in 2023.
  • Per our database at Business Quant, Stoke Therapeutics' Current Deferred Revenue surged by 261.90% in 2024 and then plummeted by 81.77% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Current Deferred Revenue (Quarterly) stood at $14.9 million in 2022, then rose by 2.88% to $15.3 million in 2023, then rose by 24.05% to $19.0 million in 2024, then crashed by 81.77% to $5.8 million in 2025.
  • Its Current Deferred Revenue was $5.8 million in Q3 2025, compared to $8.7 million in Q2 2025 and $18.2 million in Q1 2025.